Menu Search
Equities

Bayer AG

BAYRY:PKC

Bayer AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.09
  • Today's Change-0.05 / -0.97%
  • Shares traded1.60m
  • 1 Year change-44.91%
  • Beta1.0407
Data delayed at least 15 minutes, as of Nov 21 2024 21:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Bayer AG's revenues fell -6.11% from 50.74bn to 47.64bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 4.15bn to a loss of 2.94bn.
Gross margin57.14%
Net profit margin-1.87%
Operating margin4.24%
Return on assets-0.78%
Return on equity-2.75%
Return on investment-1.06%
More ▼

Cash flow in EURView more

In 2023, Bayer AG increased its cash reserves by 14.23%, or 736.00m. The company earned 5.12bn from its operations for a Cash Flow Margin of 10.74%. In addition the company used 3.52bn on investing activities and also paid 679.00m in financing cash flows.
Cash flow per share1.95
Price/Cash flow per share2.66
Book value per share8.20
Tangible book value per share-5.28
More ▼

Balance sheet in EURView more

Bayer AG has a Debt to Total Capital ratio of 57.28%, a lower figure than the previous year's 105.19%.
Current ratio1.32
Quick ratio0.8059
Total debt/total equity1.35
Total debt/total capital0.5728
More ▼

Growth rates in EUR

Year on year, growth in earnings per share excluding extraordinary items dropped -170.87%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		76.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.